• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Nextcure And Simcere To Present SIM0505 Phase 1 Data At ASCO 2026

    FIRSTWORD PHARMA

    Nextcure Gets Fast Track For SIM0505 (CDH6 ADC) In Ovarian Cancer

    GLOBENEWSWIRE

    Nextcure Updates Business And Releases 2025 Financials

    GLOBENEWSWIRE

    Nextcure Provides Business Update

    GLOBENEWSWIRE

    Nextcure To Present At Piper Sandler Healthcare Conference

    GLOBENEWSWIRE

    NextCure`s $21.5M At-Market Common Stock Offering Under Nasdaq

    GLOBENEWSWIRE

    Nextcure Updates Business & Reports Q3 2025 Financials

    GLOBENEWSWIRE

    Nextcure And Simcere Zaiming Expand Phase 1 Trial Of SIM0505

    GLOBENEWSWIRE

    NextCure Reports Second Quarter 2025 Financial Results, Business

    GLOBENEWSWIRE

    Anti-Siglec-15 Therapy Aids Bone Health in Mouse Study

    GLOBENEWSWIRE

    NextCure Joins China-ADC Gold Rush with $745M Simcere Deal

    BIOSPACE

    NextCure stops programs to take ADC fight to Big Pharma trio

    FIERCE BIOTECH

    NextCure Reports Preclinical & Biomarker Data at SITC Meeting

    GLOBENEWSWIRE

    NextCure To Give Two Presentations At SITC Annual Meeting

    GLOBENEWSWIRE

    NextCure Presented NC410 Phase 1b Results At ESMO 2024

    GLOBENEWSWIRE

    NextCure Presents NC410-Pembrolizumab Combo Data At ASCO 2024

    GLOBENEWSWIRE

    NextCure Q1 2024 Results, Business Update

    GLOBENEWSWIRE

    NextCure to Present NC410 + Pembrolizumab Phase 1b Data at ASCO 2024

    GLOBENEWSWIRE

    NextCure and LCB Present Preclinical Data on B7-H4 ADC at AACR 2024

    GLOBENEWSWIRE

    NextCure Provides Business Update and Reports Full Year 2023 Financial Results

    GLOBENEWSWIRE

    NextCure jettisons mAB to focus on ADC aimed at same target

    FIERCE BIOTECH

    A Phase 2 Study of NC318 with Pembrolizumab Demonstrates Clinical Activity

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.